
|Articles|March 31, 2023
Recommendations for Accelerating Cell and Gene Therapies
Author(s)Cognizant
While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.
Trending on PharmExec
1
Novartis to Layoff 322 NJ Employees: Report
2
Launch is Just the Beginning: Rare Disease Care Requires Durability
3
“AI as Reinvention”: Transforming the Business of Medicine
4
Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement
5